Characterization of renal injury in non‐squamous non‐small cell lung cancer patients treated with pemetrexed: A single‐center retrospective study
Abstract Introduction Pemetrexed is a key therapeutic agent for advanced non‐squamous non‐small cell lung cancer (Nsq‐NSCLC), yet it is associated with renal toxicity. This study aims to elucidate the incidence, risk factors, and survival impact of renal injury in patients with Nsq‐NSCLC treated wit...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.15470 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850256165606260736 |
|---|---|
| author | Yang Wu Kang Miao Minjiang Chen Yan Xu Wei Zhong Hanping Wang Xiaoyan Si Xiaotong Zhang Li Zhang Jing Zhao Mengzhao Wang |
| author_facet | Yang Wu Kang Miao Minjiang Chen Yan Xu Wei Zhong Hanping Wang Xiaoyan Si Xiaotong Zhang Li Zhang Jing Zhao Mengzhao Wang |
| author_sort | Yang Wu |
| collection | DOAJ |
| description | Abstract Introduction Pemetrexed is a key therapeutic agent for advanced non‐squamous non‐small cell lung cancer (Nsq‐NSCLC), yet it is associated with renal toxicity. This study aims to elucidate the incidence, risk factors, and survival impact of renal injury in patients with Nsq‐NSCLC treated with pemetrexed. Methods We conducted a retrospective study including 136 patients with Nsq‐NSCLC treated with pemetrexed. Data on demographics, renal function, progression‐free survival (PFS), and overall survival (OS) were collected. Renal injury was defined as a reduction above 25% in estimated glomerular filtration rate (eGFR) from baseline. Its associated risk factors were analyzed using logistic regression, and impact on survival was analyzed using log‐rank test. The creatinine clearance rate (CCr) was calculated, and a CCr < 45 mL/min served as a contraindication for continuing pemetrexed. Results The study found a 31.6% (43/136) incidence of renal injury, with 9.6% (13/136) having CCr < 45 mL/min and discontinuing pemetrexed. Univariate and multivariate analyses identified factors significantly associated with increased renal injury risk including older age, use of cisplatin, and higher number of pemetrexed cycles. The patients with renal injury had a median PFS (mPFS) of 13.5 months and a median OS (mOS) of 36.0 months, while the patients without had an mPFS of 9.0 months and an mOS of 35.0 months, and these differences were not statistically significant. Conclusion Renal injury is a considerable complication in patients with Nsq‐NSCLC undergoing pemetrexed treatment, with age, platinum type, and pemetrexed treatment cycles as key risk factors. These findings highlight the necessity for careful renal monitoring in this patient population. |
| format | Article |
| id | doaj-art-0d5d4e2c1f10469fb67293d7fd52fab6 |
| institution | OA Journals |
| issn | 1759-7706 1759-7714 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj-art-0d5d4e2c1f10469fb67293d7fd52fab62025-08-20T01:56:42ZengWileyThoracic Cancer1759-77061759-77142024-12-0115352474248510.1111/1759-7714.15470Characterization of renal injury in non‐squamous non‐small cell lung cancer patients treated with pemetrexed: A single‐center retrospective studyYang Wu0Kang Miao1Minjiang Chen2Yan Xu3Wei Zhong4Hanping Wang5Xiaoyan Si6Xiaotong Zhang7Li Zhang8Jing Zhao9Mengzhao Wang10Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College Hospital College Chinese Academy of Medical Sciences Beijing ChinaDepartment of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College Hospital College Chinese Academy of Medical Sciences Beijing ChinaDepartment of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College Hospital College Chinese Academy of Medical Sciences Beijing ChinaDepartment of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College Hospital College Chinese Academy of Medical Sciences Beijing ChinaDepartment of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College Hospital College Chinese Academy of Medical Sciences Beijing ChinaDepartment of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College Hospital College Chinese Academy of Medical Sciences Beijing ChinaDepartment of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College Hospital College Chinese Academy of Medical Sciences Beijing ChinaDepartment of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College Hospital College Chinese Academy of Medical Sciences Beijing ChinaDepartment of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College Hospital College Chinese Academy of Medical Sciences Beijing ChinaDepartment of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College Hospital College Chinese Academy of Medical Sciences Beijing ChinaDepartment of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College Hospital College Chinese Academy of Medical Sciences Beijing ChinaAbstract Introduction Pemetrexed is a key therapeutic agent for advanced non‐squamous non‐small cell lung cancer (Nsq‐NSCLC), yet it is associated with renal toxicity. This study aims to elucidate the incidence, risk factors, and survival impact of renal injury in patients with Nsq‐NSCLC treated with pemetrexed. Methods We conducted a retrospective study including 136 patients with Nsq‐NSCLC treated with pemetrexed. Data on demographics, renal function, progression‐free survival (PFS), and overall survival (OS) were collected. Renal injury was defined as a reduction above 25% in estimated glomerular filtration rate (eGFR) from baseline. Its associated risk factors were analyzed using logistic regression, and impact on survival was analyzed using log‐rank test. The creatinine clearance rate (CCr) was calculated, and a CCr < 45 mL/min served as a contraindication for continuing pemetrexed. Results The study found a 31.6% (43/136) incidence of renal injury, with 9.6% (13/136) having CCr < 45 mL/min and discontinuing pemetrexed. Univariate and multivariate analyses identified factors significantly associated with increased renal injury risk including older age, use of cisplatin, and higher number of pemetrexed cycles. The patients with renal injury had a median PFS (mPFS) of 13.5 months and a median OS (mOS) of 36.0 months, while the patients without had an mPFS of 9.0 months and an mOS of 35.0 months, and these differences were not statistically significant. Conclusion Renal injury is a considerable complication in patients with Nsq‐NSCLC undergoing pemetrexed treatment, with age, platinum type, and pemetrexed treatment cycles as key risk factors. These findings highlight the necessity for careful renal monitoring in this patient population.https://doi.org/10.1111/1759-7714.15470Nsq‐NSCLCpemetrexedrenal injurysurvival |
| spellingShingle | Yang Wu Kang Miao Minjiang Chen Yan Xu Wei Zhong Hanping Wang Xiaoyan Si Xiaotong Zhang Li Zhang Jing Zhao Mengzhao Wang Characterization of renal injury in non‐squamous non‐small cell lung cancer patients treated with pemetrexed: A single‐center retrospective study Thoracic Cancer Nsq‐NSCLC pemetrexed renal injury survival |
| title | Characterization of renal injury in non‐squamous non‐small cell lung cancer patients treated with pemetrexed: A single‐center retrospective study |
| title_full | Characterization of renal injury in non‐squamous non‐small cell lung cancer patients treated with pemetrexed: A single‐center retrospective study |
| title_fullStr | Characterization of renal injury in non‐squamous non‐small cell lung cancer patients treated with pemetrexed: A single‐center retrospective study |
| title_full_unstemmed | Characterization of renal injury in non‐squamous non‐small cell lung cancer patients treated with pemetrexed: A single‐center retrospective study |
| title_short | Characterization of renal injury in non‐squamous non‐small cell lung cancer patients treated with pemetrexed: A single‐center retrospective study |
| title_sort | characterization of renal injury in non squamous non small cell lung cancer patients treated with pemetrexed a single center retrospective study |
| topic | Nsq‐NSCLC pemetrexed renal injury survival |
| url | https://doi.org/10.1111/1759-7714.15470 |
| work_keys_str_mv | AT yangwu characterizationofrenalinjuryinnonsquamousnonsmallcelllungcancerpatientstreatedwithpemetrexedasinglecenterretrospectivestudy AT kangmiao characterizationofrenalinjuryinnonsquamousnonsmallcelllungcancerpatientstreatedwithpemetrexedasinglecenterretrospectivestudy AT minjiangchen characterizationofrenalinjuryinnonsquamousnonsmallcelllungcancerpatientstreatedwithpemetrexedasinglecenterretrospectivestudy AT yanxu characterizationofrenalinjuryinnonsquamousnonsmallcelllungcancerpatientstreatedwithpemetrexedasinglecenterretrospectivestudy AT weizhong characterizationofrenalinjuryinnonsquamousnonsmallcelllungcancerpatientstreatedwithpemetrexedasinglecenterretrospectivestudy AT hanpingwang characterizationofrenalinjuryinnonsquamousnonsmallcelllungcancerpatientstreatedwithpemetrexedasinglecenterretrospectivestudy AT xiaoyansi characterizationofrenalinjuryinnonsquamousnonsmallcelllungcancerpatientstreatedwithpemetrexedasinglecenterretrospectivestudy AT xiaotongzhang characterizationofrenalinjuryinnonsquamousnonsmallcelllungcancerpatientstreatedwithpemetrexedasinglecenterretrospectivestudy AT lizhang characterizationofrenalinjuryinnonsquamousnonsmallcelllungcancerpatientstreatedwithpemetrexedasinglecenterretrospectivestudy AT jingzhao characterizationofrenalinjuryinnonsquamousnonsmallcelllungcancerpatientstreatedwithpemetrexedasinglecenterretrospectivestudy AT mengzhaowang characterizationofrenalinjuryinnonsquamousnonsmallcelllungcancerpatientstreatedwithpemetrexedasinglecenterretrospectivestudy |